Laennec Iv
Chronic Liver Disease
Green Cross WellbeingPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Chronic Liver Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Heplisav-B Mercy Medical Center | Phase 4 | BB |
Pirfenidone Grupo Mexicano para el Estudios de las Enfermedades Hepaticas | Phase 2 | B |
N-Acetyl-L-Cysteine Grupo Mexicano para el Estudios de las Enfermedades Hepaticas | Phase 2 | B |
Colesevelam Foundation for Liver Research | Phase 2/3 | B |
HUMAN PLACENTA HYDROLYSATE Green Cross Wellbeing | Phase 3 | B |
View all 13 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →